EUVIMEDEUVIMED entdecken
Crossref

Tremelimumab (Imjudo) for Metastatic NSCLC

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669h ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved tremelimumab-actl (Imjudo – AstraZeneca), a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, for use in combination with the programmed death-ligand 1 (PD-L1) blocking antibody durvalumab (Imfinzi) and platinum-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

ImfinziImjudoadverse effectsdosagedurvalumabefficacylactationlung cancerpregnancysafetytremelimumab

Substanzen

tremelimumabAntibodies, Monoclonal, Humanized

Zitieren

APA

(2023). Tremelimumab (Imjudo) for Metastatic NSCLC. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669h

Vancouver

Tremelimumab (Imjudo) for Metastatic NSCLC. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669h

BibTeX
@article{euvimed2023,
  title = {Tremelimumab (Imjudo) for Metastatic NSCLC},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669h}
}
Kostenlos starten →